If bioidentical hormone replacement therapy sounds appealing, the reason is often simple.
"Natural" can feel safer than a prescription label.
That is the gap. Bioidentical marketing can make a custom hormone sound cleaner than ordinary menopause care, even when FDA-approved bioidentical options exist.
The American College of Obstetricians and Gynecologists 2023 Clinical Consensus says evidence behind those safety and effectiveness claims is lacking. It also says compounded bioidentical menopausal hormone therapy should not be prescribed routinely when FDA-approved options are available. [1]
That is not the same as saying every compounded hormone is categorically inappropriate. FDA describes compounding as an important option when an FDA-approved medication is not medically appropriate for a specific patient. [7]
For readers, the question is not whether a hormone sounds natural.
It is whether the exact product, dose, route, and monitoring plan have evidence behind them.
Bioidentical is a chemistry word, not a safety grade
"Bioidentical" usually means the hormone is similar to a hormone the body makes.
That can describe some FDA-approved estradiol and progesterone products. It can also appear in marketing for custom compounded creams, capsules, troches, and pellets.
Those are not the same regulatory question.
FDA-approved menopause hormone products have product-specific labels, doses, manufacturing standards, and risk information.
A custom compound can serve real patient-specific needs, such as a documented allergy, route problem, dose need, excipient issue, or formulation difference. But it does not receive the same product-level FDA approval for safety and effectiveness before use.
The 2022 North American Menopause Society position statement keeps this distinction central when discussing hormone therapy choices after menopause. [2]
Another 2022 review raised the same concern: women may choose cBHT because they believe it is safer than standard hormone therapy, even though that belief is not established by outcome data. [4]
The National Academies review also treated compounded bioidentical hormone therapy as a safety, effectiveness, and use question that needs better evidence and oversight. [5]
The FDA's menopause hormone medicine page lists approved hormone medicines and gives a useful safety frame: hormone therapy is not for people with unusual vaginal bleeding, certain cancers, prior clot, stroke, heart attack, bleeding disorder, liver disease, serious hormone-medicine allergy, or pregnancy concern. It also lists approved estradiol and micronized progesterone products among menopause hormone medicines. [6]
Three meanings of bioidentical HRT
| Phrase people use | What it may mean | What to ask |
|---|---|---|
| FDA-approved bioidentical estradiol | An approved patch, gel, spray, pill, vaginal product, or other estradiol formulation. | What symptom is being treated, and does route change clot, bleeding, or uterus-status planning? |
| FDA-approved micronized progesterone | A progesterone product used when endometrial protection or another specific indication fits. | Is the uterus present, what dose/duration is being used, and are allergy or sedation issues relevant? |
| Compounded bioidentical hormone replacement therapy | A custom-mixed product from a compounding pharmacy. | Why is an approved product not suitable, and how will dose consistency, adverse effects, and monitoring be handled? |
| Pellet or multi-hormone program | Longer-acting exposure, often including testosterone or multiple hormones. | What happens if side effects occur, levels become supraphysiologic, or bleeding/acne/hair/voice symptoms appear? |
That table is the core decision. The word "bioidentical" does not tell you whether the product is FDA-approved, compounded, dose-consistent, easy to stop, or appropriate for the symptom.
The trial evidence leaves the big safety questions open
A 2022 review examined compounded bioidentical hormone therapy in peri- and postmenopausal women.
It included 29 randomized trials reported in 40 articles, with 1,808 participants. [3]
That sounds substantial until you look at the endpoints.
Short-term trials did not show adverse changes in lipid profile or glucose metabolism. Compounded vaginal androgens also appeared to improve vaginal atrophy symptoms. [3]
But the same review said clinical heart events, endometrial biopsy outcomes, breast cancer risk, and other long-term outcomes were not well studied. [3]
That is the patient translation.
A short-term trial signal does not establish that a compounded hormone plan is safer for the outcomes women worry about most.
Why symptom matching is not the same as dose control
Compounded hormone programs often use symptom forms or hormone tests to adjust doses.
Symptoms matter. They are not enough by themselves.
Hot flashes, broken sleep, weight change, low desire, vaginal dryness, mood shifts, and fatigue can overlap.
A dose change that feels logical can still miss anemia, thyroid disease, sleep apnea, depression, medication effects, insulin resistance, or genitourinary syndrome of menopause.
This is why clinician review should be the next step.
The value is not selling a more romantic hormone story. The value is sorting the symptom target, the contraindications, the route, and the monitoring in a structured hormone assessment.
What a safer hormone conversation sounds like
The safer first question is: can an FDA-approved product address the goal?
For hot flashes or night sweats, ask whether hormone therapy is appropriate.
Also ask whether transdermal estrogen changes clot-risk counseling for this patient, and whether progesterone is needed because the uterus is present.
For vaginal dryness or painful sex, the answer may be local vaginal estrogen, prasterone, ospemifene, moisturizers, lubricants, or pelvic-floor care.
That is different from a systemic hormone plan.
For low desire, it may mean separating genitourinary syndrome of menopause from hypoactive sexual desire disorder.
Testosterone should be reviewed only under the evidence boundaries for women.
Compounding can still have a patient-specific place. A patient might have a true excipient allergy, a route problem, a dose need, or a formulation reason that an approved product cannot meet. That is a reason to document the plan clearly, not a shortcut around evidence.
Decision table before compounding
| Question | Safer interpretation |
|---|---|
| Is an FDA-approved product available? | Use the approved option first when it can meet the symptom goal. |
| Is there a true allergy, route problem, dose need, excipient issue, or formulation reason? | Compounding may be discussed as a documented patient-specific option. |
| Is the claim "natural" or "bioidentical"? | Those words do not establish safer dosing, better monitoring, or better outcomes. |
| Is pellet or multi-hormone dosing proposed? | Ask how levels, side effects, bleeding, and supraphysiologic exposure will be handled. |
| Are symptoms broad or nonspecific? | Check thyroid, anemia, sleep, mood, genitourinary syndrome of menopause, medication, and metabolic causes before escalating hormones. |
Red flags before using compounded BHRT
Red flags include unusual or postmenopausal bleeding, breast cancer or estrogen-sensitive cancer history, prior deep vein thrombosis/pulmonary embolism, stroke, heart attack, liver disease, known thrombophilia, pregnancy possibility, severe migraine change, new breast symptoms, unexplained pelvic pain, or a plan that uses pellets or testosterone without clear dose limits and stop rules.
Process red flags matter too: no FDA-approved option was discussed, hormone saliva/urine testing is used as the main dosing logic, the product combines several hormones without a clear target, side effects are described as detox or adjustment, or the clinician cannot explain what result would make the product stop.
| Decision point | Reasonable patient-specific reason | Weak reason |
|---|---|---|
| Allergy | A true excipient allergy prevents use of the approved product. | "Compounded is cleaner" without naming the allergen. |
| Route | Available approved routes cannot meet a documented need. | A custom cream is offered before approved patches, gels, pills, or local options are discussed. |
| Dose | A clinically necessary dose is not available in approved products. | Dose is escalated to chase energy, mood, weight, or a hormone number. |
| Monitoring | Symptoms, bleeding, side effects, and risk factors are reviewed at defined intervals. | Saliva or urine testing drives dosing despite limited interpretation data. |
| Testosterone | hypoactive sexual desire disorder is assessed and alternatives are reviewed. | Testosterone is added for general vitality, weight, anxiety, or anti-aging. |
What to ask your clinician
Ask:
- Which specific symptom are we treating: hot flashes, sleep disruption, genitourinary syndrome of menopause, painful sex, low desire, mood, or something else?
- Is there an FDA-approved bioidentical product that can meet this goal with clearer labeling and dose consistency?
- What documented allergy, dose need, route problem, excipient issue, or formulation reason makes compounding useful for me?
- Which pharmacy, ingredients, strength, route, and refill process will be used?
- How will bleeding, breast risk, endometrial protection, clot or stroke risk, liver risk, and side effects be monitored?
- Are hormone saliva, urine, or serum tests being used to guide dosing, and what evidence supports that approach?
- What result would make us stop the compounded product and return to approved options?
Bottom line
The phrase "compounded bioidentical" should trigger specific questions, not automatic rejection or automatic trust.
Ask which symptom is being treated, whether an FDA-approved option exists, what patient-specific reason makes compounding useful, how the dose and ingredients will be checked, what side effects should stop treatment, and what evidence applies to the exact route being used.
If the answer is mostly "it is natural," the evidence has not caught up with the marketing.
Related reading:
- Hormone Therapy After Menopause: Benefits, Risks, and Timing.
- Who Should Avoid hormone replacement therapy After Menopause?.
- Progesterone vs Progestin in hormone replacement therapy.
References
[1] Compounded Bioidentical Menopausal Hormone Therapy: ACOG Clinical Consensus No. 6. Obstet Gynecol. 2023;142(5):1266-1273. doi:10.1097/aog.0000000000005395 https://pubmed.ncbi.nlm.nih.gov/37856860/
[2] “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/gme.0000000000002028 https://pubmed.ncbi.nlm.nih.gov/35797481/
[3] Liu Y, Yuan Y, Day AJ, et al. Safety and efficacy of compounded bioidentical hormone therapy (cBHT) in perimenopausal and postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Menopause. 2022;29(4):465-482. doi:10.1097/gme.0000000000001937 https://pubmed.ncbi.nlm.nih.gov/35357369/
[4] Pinkerton JV. Concerns About Compounded Bioidentical Menopausal Hormone Therapy. Cancer J. 2022;28(3):241-245. doi:10.1097/ppo.0000000000000597 https://pubmed.ncbi.nlm.nih.gov/35594471/
[5] National Academies. The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use. https://pubmed.ncbi.nlm.nih.gov/33048485/
[6] FDA. Menopause: Medicines to Help You. https://www.fda.gov/consumers/free-publications-women/menopause-medicines-help-you
[7] FDA. Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers